Symbols / HRTX Stock $0.48 +8.48% Heron Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
HRTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Craig Alexander Collard
Exch · Country NCM · United States
Market Cap 91.74M
Enterprise Value 182.47M
Income -30.94M
Sales 150.71M
FCF (ttm) -18.44M
Book/sh 0.04
Cash/sh 0.24
Employees 128
Insider 10d —
IPO Aug 26, 1987
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E inf
PEG —
P/S 0.61
P/B 11.27
P/C —
EV/EBITDA -22.35
EV/Sales 1.21
Quick Ratio 1.42
Current Ratio 2.53
Debt/Eq 1,550.12
LT Debt/Eq —
EPS (ttm) -0.18
EPS next Y 0.00
EPS Growth —
Revenue Growth -10.80%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-07
Earnings (prior) 2026-05-11
ROA -2.71%
ROE —
ROIC —
Gross Margin 62.80%
Oper. Margin -13.73%
Profit Margin -20.53%
Shs Outstand 189.28M
Shs Float 135.48M
Insider Own 0.88%
Instit Own 83.29%
Short Float 26.72%
Short Ratio 15.56
Short Interest 39.68M
52W High 2.30
vs 52W High -78.93%
52W Low 0.43
vs 52W Low 12.72%
Beta 1.71
Impl. Vol. 41.16%
Rel Volume 1.36
Avg Volume 2.60M
Volume 3.54M
Target (mean) $3.00
Tgt Median $3.00
Tgt Low $2.00
Tgt High $4.00
# Analysts 2
Recom Buy
Prev Close $0.45
Price $0.48
Change 8.48%
About

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.48
Latest analyst target
3. DCF / Fair value
$-1.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.48
Low
$2.00
High
$4.00
Mean
$3.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-03 main HC Wainwright & Co. Buy → Buy $2
2026-06-03 down Needham Buy → Hold —
2026-01-09 reit HC Wainwright & Co. Buy → Buy $6
2025-08-08 main Needham Buy → Buy $3
2025-06-09 init HC Wainwright & Co. — → Buy $6
2025-04-11 reit Needham Buy → Buy $4
2025-02-28 reit Needham Buy → Buy $4
2024-12-04 reit Needham Buy → Buy $4
2024-11-13 main Needham Buy → Buy $4
2024-09-25 reit Needham Buy → Buy $5
2024-08-07 reit Needham Buy → Buy $5
2024-06-13 init Rodman & Renshaw — → Buy $7
2024-05-16 reit Needham Buy → Buy $5
2024-05-08 reit Needham Buy → Buy $5
2024-04-23 init Capital One — → Overweight $6
2024-04-11 reit Needham Buy → Buy $5
2024-03-13 main Needham Buy → Buy $5
2023-11-15 main Needham Buy → Buy $4
2023-08-15 reit Needham Buy → Buy $5
2023-07-25 main Needham Buy → Buy $5
News
RSS: Latest HRTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-06 HENSLEY MARK EARL Chief Operating Officer — 125,000 — —
2026-04-30 FORBES WILLIAM P Officer — 23,464 — —
2026-04-30 COLLARD CRAIG ALEXANDER Chief Executive Officer — 84,810 — —
2026-04-30 DUARTE IRA Chief Financial Officer — 25,229 — —
2026-04-30 HENSLEY MARK EARL Chief Operating Officer — 11,770 — —
2026-04-17 FORBES WILLIAM P Officer — 3,874 — —
2026-04-17 COLLARD CRAIG ALEXANDER Chief Executive Officer — 13,797 — —
2026-04-17 DUARTE IRA Chief Financial Officer — 3,874 — —
2026-04-02 COLLARD CRAIG ALEXANDER Chief Executive Officer — 62,500 — —
2026-01-30 CUSACK THOMAS J Director — 53,960 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
154.90
+7.36%
144.28
+13.57%
127.04
+17.99%
107.67
Operating Revenue
154.90
+7.36%
144.28
+13.57%
127.04
+17.99%
107.67
Cost Of Revenue
41.35
+6.98%
38.65
-40.64%
65.11
+18.64%
54.87
Reconciled Cost Of Revenue
41.35
+6.98%
38.65
-40.64%
65.11
+18.64%
54.87
Gross Profit
113.56
+7.50%
105.64
+70.55%
61.94
+17.31%
52.80
Operating Expense
116.09
-0.91%
117.17
-32.10%
172.55
-24.14%
227.46
Research And Development
12.43
-25.50%
16.68
-57.37%
39.13
-52.68%
82.70
Selling General And Administration
103.67
+3.17%
100.48
-24.69%
133.42
-7.83%
144.75
Selling And Marketing Expense
49.06
+4.20%
47.09
-30.39%
67.64
-18.02%
82.51
General And Administrative Expense
54.60
+2.26%
53.40
-18.82%
65.78
+5.69%
62.24
Other Gand A
54.60
+2.26%
53.40
-18.82%
65.78
+5.69%
62.24
Total Expenses
157.44
+1.05%
155.81
-34.44%
237.66
-15.82%
282.33
Operating Income
-2.54
+77.98%
-11.53
+89.58%
-110.61
+36.67%
-174.66
Total Operating Income As Reported
-2.54
+77.98%
-11.53
+89.58%
-110.61
+36.67%
-174.66
EBITDA
-8.28
-63.69%
-5.06
+95.13%
-103.79
+41.25%
-176.66
Normalized EBITDA
3.06
+160.58%
-5.06
+95.13%
-103.79
+41.25%
-176.66
Reconciled Depreciation
2.31
-7.14%
2.49
-14.04%
2.90
+0.35%
2.89
EBIT
-10.59
-40.30%
-7.55
+92.93%
-106.69
+40.58%
-179.55
Total Unusual Items
-11.34
0.00
0.00
—
Total Unusual Items Excluding Goodwill
-11.34
0.00
0.00
—
Special Income Charges
-11.34
0.00
0.00
—
Other Special Charges
11.34
—
—
—
Net Income
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Pretax Income
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Net Non Operating Interest Income Expense
-7.66
-208.50%
-2.48
-392.46%
-0.50
+39.71%
-0.84
Interest Expense Non Operating
9.61
+59.23%
6.03
+55.95%
3.87
+56.35%
2.47
Net Interest Income
-7.66
-208.50%
-2.48
-392.46%
-0.50
+39.71%
-0.84
Interest Expense
9.61
+59.23%
6.03
+55.95%
3.87
+56.35%
2.47
Interest Income Non Operating
1.95
-45.13%
3.55
+5.53%
3.36
+105.37%
1.64
Interest Income
1.95
-45.13%
3.55
+5.53%
3.36
+105.37%
1.64
Other Income Expense
-10.00
-2425.58%
0.43
-23.21%
0.56
+108.58%
-6.53
Other Non Operating Income Expenses
1.34
+211.40%
0.43
-23.21%
0.56
+108.58%
-6.53
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Net Income From Continuing Operation Net Minority Interest
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Net Income From Continuing And Discontinued Operation
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Net Income Continuous Operations
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Normalized Income
-8.86
+34.79%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Net Income Common Stockholders
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Diluted EPS
-0.12
-33.33%
-0.09
+88.75%
-0.80
+52.10%
-1.67
Basic EPS
-0.12
-33.33%
-0.09
+88.75%
-0.80
+52.10%
-1.67
Basic Average Shares
166.71
+9.35%
152.45
+10.36%
138.13
+26.73%
109.00
Diluted Average Shares
166.71
+9.35%
152.45
+10.36%
138.13
+26.73%
109.00
Diluted NI Availto Com Stockholders
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
255.88
+9.75%
233.15
+4.78%
222.51
-11.33%
250.95
Current Assets
238.07
+13.90%
209.01
+10.72%
188.77
-8.11%
205.44
Cash Cash Equivalents And Short Term Investments
46.63
-21.34%
59.28
-26.27%
80.41
-5.24%
84.85
Cash And Cash Equivalents
28.65
+11.03%
25.80
-10.03%
28.68
+86.65%
15.36
Other Short Term Investments
17.98
-46.29%
33.48
-35.28%
51.73
-25.55%
69.49
Receivables
89.59
+13.57%
78.88
+31.17%
60.14
+15.54%
52.05
Accounts Receivable
89.59
+13.57%
78.88
+31.17%
60.14
+15.54%
52.05
Inventory
92.75
+74.47%
53.16
+26.24%
42.11
-22.84%
54.57
Raw Materials
59.25
+200.26%
19.73
+11.85%
17.64
+16.56%
15.14
Work In Process
26.61
-2.12%
27.19
+86.87%
14.55
-29.79%
20.72
Finished Goods
6.88
+10.36%
6.24
-37.11%
9.92
-47.00%
18.71
Prepaid Assets
—
—
—
—
Other Current Assets
9.10
-48.55%
17.69
+189.15%
6.12
-56.18%
13.96
Total Non Current Assets
17.81
-26.20%
24.13
-28.46%
33.73
-25.89%
45.52
Net PPE
12.40
-29.73%
17.65
-31.07%
25.60
-14.09%
29.80
Gross PPE
25.28
-28.77%
35.50
-16.74%
42.63
-3.32%
44.10
Accumulated Depreciation
-12.88
+27.83%
-17.85
-4.81%
-17.03
-19.14%
-14.29
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.19
-90.59%
2.06
-18.21%
2.52
+1.29%
2.49
Other Properties
25.09
-24.27%
33.13
-16.05%
39.47
-3.66%
40.96
Leases
0.00
-100.00%
0.31
-52.55%
0.65
+0.00%
0.65
Other Non Current Assets
5.41
-16.58%
6.48
-20.24%
8.13
-48.27%
15.71
Total Liabilities Net Minority Interest
241.54
-9.47%
266.80
+4.02%
256.48
+8.05%
237.38
Current Liabilities
96.10
+5.07%
91.46
+14.77%
79.69
-3.24%
82.36
Payables And Accrued Expenses
87.48
+8.73%
80.46
+17.02%
68.76
+0.55%
68.38
Payables
8.99
-23.19%
11.71
+208.21%
3.80
+5.88%
3.59
Accounts Payable
8.99
-23.19%
11.71
+208.21%
3.80
+5.88%
3.59
Current Accrued Expenses
78.49
+14.17%
68.75
+5.83%
64.96
+0.26%
64.79
Pensionand Other Post Retirement Benefit Plans Current
8.61
+8.18%
7.96
+1.40%
7.85
-30.39%
11.28
Current Debt And Capital Lease Obligation
—
3.04
-1.24%
3.08
+14.14%
2.69
Current Capital Lease Obligation
0.00
-100.00%
3.04
-1.24%
3.08
+14.14%
2.69
Total Non Current Liabilities Net Minority Interest
145.45
-17.05%
175.34
-0.82%
176.79
+14.04%
155.02
Long Term Debt And Capital Lease Obligation
140.64
-19.51%
174.73
-1.03%
176.55
+14.06%
154.78
Long Term Debt
140.64
-19.51%
174.73
+0.56%
173.75
+16.39%
149.28
Long Term Capital Lease Obligation
—
0.00
-100.00%
2.80
-49.08%
5.50
Other Non Current Liabilities
4.81
+681.79%
0.61
+155.19%
0.24
+0.00%
0.24
Stockholders Equity
14.33
+142.59%
-33.65
+0.95%
-33.97
-350.32%
13.57
Common Stock Equity
13.28
+139.47%
-33.65
+0.95%
-33.97
-350.32%
13.57
Capital Stock
2.93
+92.83%
1.52
+1.20%
1.50
+26.20%
1.19
Common Stock
1.88
+23.80%
1.52
+1.20%
1.50
+26.20%
1.19
Preferred Stock
1.05
0.00
0.00
0.00
Share Issued
188.31
+23.79%
152.13
+1.23%
150.29
+26.13%
119.16
Ordinary Shares Number
188.31
+23.79%
152.13
+1.23%
150.29
+26.13%
119.16
Additional Paid In Capital
1,951.18
+3.54%
1,884.41
+0.74%
1,870.53
+3.47%
1,807.86
Retained Earnings
-1,939.79
-1.05%
-1,919.59
-0.71%
-1,906.01
-6.16%
-1,795.45
Gains Losses Not Affecting Retained Earnings
0.00
-69.23%
0.01
+0.00%
0.01
+168.42%
-0.02
Other Equity Adjustments
0.00
-69.23%
0.01
+0.00%
0.01
+168.42%
-0.02
Total Equity Gross Minority Interest
14.33
+142.59%
-33.65
+0.95%
-33.97
-350.32%
13.57
Total Capitalization
154.97
+9.85%
141.07
+0.93%
139.78
-14.17%
162.86
Working Capital
141.97
+20.77%
117.56
+7.76%
109.09
-11.37%
123.08
Invested Capital
153.92
+9.11%
141.07
+0.93%
139.78
-14.17%
162.86
Total Debt
140.64
-20.88%
177.76
-1.04%
179.63
+14.07%
157.48
Net Debt
111.99
-24.80%
148.92
+2.65%
145.08
+8.33%
133.92
Capital Lease Obligations
0.00
-100.00%
3.04
-48.31%
5.88
-28.29%
8.19
Net Tangible Assets
14.33
+142.59%
-33.65
+0.95%
-33.97
-350.32%
13.57
Tangible Book Value
13.28
+139.47%
-33.65
+0.95%
-33.97
-350.32%
13.57
Interest Payable
0.90
+281.43%
0.24
-42.48%
0.41
+338.30%
0.09
Preferred Stock Equity
1.05
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-27.59
-22.47%
-22.53
+61.68%
-58.79
+59.98%
-146.91
Cash Flow From Continuing Operating Activities
-27.59
-22.47%
-22.53
+61.68%
-58.79
+59.98%
-146.91
Net Income From Continuing Operations
-20.20
-48.71%
-13.58
+87.72%
-110.56
+39.26%
-182.02
Depreciation Amortization Depletion
2.31
-7.14%
2.49
-14.04%
2.90
+0.35%
2.89
Depreciation And Amortization
2.31
-7.14%
2.49
-14.04%
2.90
+0.35%
2.89
Other Non Cash Items
0.82
-14.98%
0.96
+183.48%
0.34
+67.82%
0.20
Stock Based Compensation
10.34
-20.24%
12.96
-60.55%
32.85
-23.56%
42.98
Asset Impairment Charge
—
—
0.62
+195.22%
0.21
Operating Gains Losses
11.75
+168.21%
4.38
+598.88%
0.63
+121.55%
0.28
Gain Loss On Sale Of PPE
0.41
-90.55%
4.38
+598.88%
0.63
+121.55%
0.28
Change In Working Capital
-31.88
-15.49%
-27.60
-264.40%
16.79
+259.81%
-10.51
Change In Receivables
-10.71
+42.88%
-18.74
-131.75%
-8.09
+51.13%
-16.55
Changes In Account Receivables
-10.71
+42.88%
-18.74
-131.75%
-8.09
+51.13%
-16.55
Change In Inventory
-31.05
-181.01%
-11.05
-188.66%
12.46
+301.31%
-6.19
Change In Prepaid Assets
0.88
+108.84%
-9.93
-164.35%
15.43
+1427.33%
1.01
Change In Payables And Accrued Expense
9.00
-25.73%
12.12
+502.46%
-3.01
-126.82%
11.22
Change In Accrued Expense
11.71
+221.05%
3.65
+220.59%
-3.03
-125.64%
11.80
Change In Payable
-2.71
-132.06%
8.47
+56360.00%
0.01
+102.60%
-0.58
Change In Account Payable
-2.71
-132.06%
8.47
+56360.00%
0.01
+102.60%
-0.58
Investing Cash Flow
16.01
-14.45%
18.71
+4.00%
18.00
+641.37%
-3.32
Cash Flow From Continuing Investing Activities
16.01
-14.45%
18.71
+4.00%
18.00
+641.37%
-3.32
Net PPE Purchase And Sale
-0.22
+86.96%
-1.68
-9.60%
-1.53
+4.13%
-1.60
Purchase Of PPE
-0.32
+81.42%
-1.71
-10.42%
-1.54
+15.34%
-1.82
Sale Of PPE
0.10
+262.96%
0.03
+107.69%
0.01
-94.27%
0.23
Capital Expenditure
-0.32
+81.42%
-1.71
-10.42%
-1.54
+15.34%
-1.82
Net Investment Purchase And Sale
16.23
-20.42%
20.39
+4.43%
19.53
+1231.34%
-1.73
Purchase Of Investment
-50.79
+50.73%
-103.09
-17.60%
-87.66
+39.83%
-145.68
Sale Of Investment
67.01
-45.73%
123.48
+15.20%
107.19
-25.54%
143.96
Financing Cash Flow
14.43
+1434.79%
0.94
-98.26%
54.11
-27.91%
75.06
Cash Flow From Continuing Financing Activities
14.43
+1434.79%
0.94
-98.26%
54.11
-27.91%
75.06
Net Issuance Payments Of Debt
-12.76
0.00
-100.00%
24.35
0.00
Issuance Of Debt
137.25
0.00
-100.00%
24.35
0.00
Repayment Of Debt
-150.00
0.00
0.00
—
Long Term Debt Issuance
137.25
0.00
-100.00%
24.35
0.00
Long Term Debt Payments
-150.00
0.00
0.00
—
Net Long Term Debt Issuance
-12.76
0.00
-100.00%
24.35
0.00
Net Common Stock Issuance
18.31
0.00
-100.00%
29.75
-60.40%
75.14
Proceeds From Stock Option Exercised
1.01
+7.77%
0.94
+46900.00%
0.00
+102.33%
-0.09
Changes In Cash
2.85
+198.96%
-2.88
-121.60%
13.31
+117.71%
-75.18
Beginning Cash Position
25.80
-10.03%
28.68
+86.65%
15.36
-83.03%
90.54
End Cash Position
28.65
+11.03%
25.80
-10.03%
28.68
+86.65%
15.36
Free Cash Flow
-27.91
-15.16%
-24.23
+59.83%
-60.33
+59.44%
-148.74
Interest Paid Supplemental Data
6.51
+33.99%
4.86
+58.88%
3.06
+35.96%
2.25
Amortization Of Securities
-0.74
+65.52%
-2.14
-23.23%
-1.74
-136.28%
-0.74
Common Stock Issuance
18.31
0.00
-100.00%
29.75
-60.40%
75.14
Issuance Of Capital Stock
26.17
0.00
-100.00%
29.75
-60.40%
75.14
Net Preferred Stock Issuance
7.86
0.00
0.00
—
Preferred Stock Issuance
7.86
0.00
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category